Drug intelligence / Profile preview

Pediococcus acidilactici PA53

Development stage: Preclinical
Lead developer: Wecare Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Pediococcus acidilactici PA53 is a probiotic bacterial strain developed and manufactured by Wecare Probiotics Co., Ltd. Sourced from traditional milk tofu, this Gram-positive lactic acid bacterium is being investigated as a live biotherapeutic product for various therapeutic applications, including non-alcoholic fatty liver disease (NAFLD), gastrointestinal health, metabolic syndrome, and emotional health. Preclinical research in murine models has demonstrated that PA53 can mitigate high-fat diet-induced NAFLD by modulating the composition of the gut microbiota, reducing systemic and hepatic inflammation, and improving metabolic parameters. The strain is deposited in international culture collections under the identifiers ATCC PTA-127865 and DSM 35158 and has achieved GRAS (Generally Recognized as Safe) status.

Brand names: WecLac PA53
Other names: Pediococcus acidilactici PA53

Beyond the preview

Go deeper on Pediococcus acidilactici PA53.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pediococcus acidilactici PA53.

Explore the full profile